LivaNova (NASDAQ:LIVN) Issues FY 2025 Earnings Guidance

Key Points

• LivaNova has updated its FY 2025 earnings guidance, projecting an EPS of 3.700-3.800 and revenue of $1.4 billion, surpassing consensus estimates.
• The company's stock rose 2.5% on Thursday, with a trading price of $48.56 and a market capitalization of $2.65 billion.
• Analysts have been rating LivaNova with an average target price of $59.29, with most maintaining a "buy" or "outperform" rating on the stock.

LivaNova (NASDAQ:LIVN - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.700-3.800 for the period, compared to the consensus estimate of 3.645. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Robert W. Baird raised their price objective on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a report on Tuesday, May 20th. Needham & Company LLC reissued a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Barclays cut their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday. One analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, LivaNova has a consensus rating of "Buy" and an average price target of $59.29.

LivaNova Price Performance

Shares of LIVN stock traded up $0.47 during trading hours on Monday, hitting $49.31. 48,497 shares of the company's stock were exchanged, compared to its average volume of 705,369. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The firm has a market cap of $2.69 billion, a P/E ratio of -12.70 and a beta of 0.92. The firm has a 50 day moving average of $44.94 and a two-hundred day moving average of $42.73. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. LivaNova's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the business posted $0.93 EPS. Sell-side analysts forecast that LivaNova will post 2.85 EPS for the current year.

Institutional Trading of LivaNova

A number of institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new position in LivaNova during the first quarter worth about $130,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock valued at $1,394,000 after acquiring an additional 1,360 shares during the period. Intech Investment Management LLC boosted its stake in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company's stock valued at $1,724,000 after purchasing an additional 7,195 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company's stock worth $6,633,000 after buying an additional 15,405 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company's stock worth $32,012,000 after buying an additional 36,094 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.